Pursuing an underdiagnosed disease: A simple imaging test for increasing suspicion of cardiac amyloidosis

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 3, 2011, Pages 467-469

  Falk, Rodney H ^a,b   Dorbala, Sharmila ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 3,3 DIPHOSPHONO 1,2 PROPANODICARBOXYLIC ACID TC 99M; ALBUMIN; AMYLOID; APROTININ TC 99M; MEDRONATE TECHNETIUM TC 99M; PREALBUMIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ALBUMIN BLOOD LEVEL; AMYLOIDOSIS; BONE SCINTISCANNING; CARDIAC IMAGING; CARDIOLOGIST; CARDIOMYOPATHY; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; HEART AMYLOIDOSIS; HEART FAILURE; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE BIOPSY; HUMAN; HYPOALBUMINEMIA; IMMUNOHISTOCHEMISTRY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; PROTEINURIA; PROTEOMICS; REVIEW; SENILE AMYLOIDOSIS; SENSITIVITY AND SPECIFICITY;

AMYLOIDOSIS; DIAGNOSTIC IMAGING; HEART DISEASES; HUMANS; RADIOACTIVE TRACERS;

EID: 79953742146     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-011-1727-y     Document Type: Review

References (23)

1. Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis 2010;52:347-61.
2. Comenzo RL. How I treat amyloidosis. Blood 2009;114:3147-57.
3. Kolstoe SE, Wood SP. Drug targets for amyloidosis. Biochem Soc Trans 2010;38:466-70.
4. Kolstoe SE, Mangione PP, Bellotti V, Taylor GW, Tennent GA, Deroo S, et al. Trapping of palindromic ligands within native transthyretin prevents amyloid formation. Proc Natl Acad Sci U S A 2010;107:20483-8.
5. Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJ, et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol 2010;148:760-7.
6. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010;468:93-7.
7. Benson MD, Kluve-Beckerman B, Zeldenrust SR, Siesky AM, Bodenmiller DM, Showalter AD, et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 2006;33:609-18.
8. Picken MM. Amyloidosis-where are we now and where are we heading? Arch Pathol Lab Med 2010;134:545-51.
9. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-84. (Pubitemid 41316518)
10. Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, et al. Usefulness and limitations of 99mTc-3, 3-diphosphono-1, 2- propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 2011. doi:10.1007/s00259-010-1642-7.
11. Glaudemans AW, Slart RH, Zeebregts CJ, Veltman NC, Tio RA, Hazenberg BP, et al. Nuclear imaging in cardiac amyloidosis. Eur J Nucl Med Mol Imaging 2009;36:702-14.
12. Han S, Chong V, Murray T, McDonagh T, Hunter J, Poon FW, et al. Preliminary experience of 99mTc-aprotinin scintigraphy in amyloidosis. Eur J Haematol 2007;79:494-500. (Pubitemid 350126671)
13. Hongo M, Urushibata K, Kai R, Takahashi W, Koizumi T, Uchikawa S, et al. Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis. Am Heart J 2002;144:122-9. (Pubitemid 34734765)
14. Falk RH, Lee VW, Rubinow A, Hood WB, Cohen AS. Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol 1983;51:826-30. (Pubitemid 13141976)
15. Gertz MA, Brown ML, Hauser MF, Kyle RA. Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis. Arch Intern Med 1987;147:1039-44. (Pubitemid 17113265)
16. Hongo M, Hirayama J, Fujii T, Yamada H, Okubo S, Kusama S, et al. Early identification of amyloid heart disease by technetium-99m-pyrophosphate scintigraphy: a study with familial amyloid polyneuropathy. Am Heart J 1987;113:654-62. (Pubitemid 17036713)
17. Lee VW, Caldarone AG, Falk RH, Rubinow A, Cohen AS. Amyloidosis of heart and liver: comparison of Tc-99m pyrophosphate and Tc-99m methylene diphosphonate for detection. Radiology 1983;148:239-42. (Pubitemid 13107818)
18. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-93. (Pubitemid 40139730)
19. Pennell DJ, Maceira AM. Magnetic resonance imaging in cardiac amyloidosis. JACC Cardiovasc Imaging 2009;2:1378-80.
20. Charkes ND, Makler Jr PT. Studies in skeletal tracer kinetics. V: Computer-simulated Tc-99m (Sn)MDP bone-scan changes in some systemic disorders: concise communication. J Nucl Med 1981;22:601-5. (Pubitemid 11067856)
21. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165:1425-9. (Pubitemid 40973426)
22. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203-12.
23. Kruger JL, Falk RH. An underdiagnosed disease? High prevalence of senile amyloidosis in a cardiac amyloid program (abstract). Amyloid 2010;17 Suppl 1:207.